Primary cutaneous CD30+ lymphoproliferative disorders: New insights into biology and therapy

Christiane Querfeld*, Timothy M. Kuzel, Joan Guitart, Steven T. Rosen

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

25 Scopus citations

Abstract

The spectrum of CD30+ lymphoproliferative diseases of the skin includes CD30+ cutaneous anaplastic large cell lymphoma, lymphomatoid papulosis, as well as borderline cases. These entities constitute the second most common group of cutaneous lymphomas according to the newly revised World Health Organization and European Organisation for Research and Treatment of Cancer consensus classification. Recent progress in immune and molecular biology, and identification of therapeutic targets have increased our understanding of these diseases and have led to novel treatment approaches. This review will provide an update on recent findings of immunologic, molecular, cytogenetic features and treatment strategies for patients with CD30+ lymphoproliferative diseases.

Original languageEnglish (US)
Pages (from-to)689-696
Number of pages8
JournalONCOLOGY
Volume21
Issue number6
StatePublished - May 1 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Primary cutaneous CD30<sup>+</sup> lymphoproliferative disorders: New insights into biology and therapy'. Together they form a unique fingerprint.

Cite this